NZ624708A - Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent - Google Patents
Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentInfo
- Publication number
- NZ624708A NZ624708A NZ624708A NZ62470811A NZ624708A NZ 624708 A NZ624708 A NZ 624708A NZ 624708 A NZ624708 A NZ 624708A NZ 62470811 A NZ62470811 A NZ 62470811A NZ 624708 A NZ624708 A NZ 624708A
- Authority
- NZ
- New Zealand
- Prior art keywords
- urate
- lowering agent
- halofenate
- methods
- gout
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 5
- 239000002253 acid Substances 0.000 title abstract 2
- 229950000958 halofenate Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- BJBCSGQLZQGGIQ-UHFFFAOYSA-N 2-acetamidoethyl 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)OCCNC(=O)C)OC1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-UHFFFAOYSA-N 0.000 title 1
- 201000005569 Gout Diseases 0.000 title 1
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 3
- 229940116269 uric acid Drugs 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 108010092464 Urate Oxidase Proteins 0.000 abstract 1
- 229940116731 Uricosuric agent Drugs 0.000 abstract 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 abstract 1
- 229960005101 febuxostat Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003383 uricosuric agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059394 WO2013066349A1 (en) | 2011-11-04 | 2011-11-04 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ624708A true NZ624708A (en) | 2015-11-27 |
Family
ID=48192533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ624708A NZ624708A (en) | 2011-11-04 | 2011-11-04 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2773336A4 (enExample) |
| JP (1) | JP6202633B2 (enExample) |
| KR (1) | KR20140121383A (enExample) |
| CN (2) | CN104066427A (enExample) |
| AU (1) | AU2011380507B2 (enExample) |
| CA (1) | CA2859686C (enExample) |
| CL (1) | CL2014001155A1 (enExample) |
| IL (1) | IL232386A0 (enExample) |
| MX (1) | MX357507B (enExample) |
| NZ (1) | NZ624708A (enExample) |
| SG (1) | SG11201402032RA (enExample) |
| WO (1) | WO2013066349A1 (enExample) |
| ZA (1) | ZA201403575B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104602686A (zh) * | 2012-04-13 | 2015-05-06 | 西玛贝医药公司 | 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法 |
| TWI705812B (zh) * | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
| JP6368756B2 (ja) * | 2016-10-20 | 2018-08-01 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 |
| CN108014108A (zh) * | 2016-11-03 | 2018-05-11 | 江苏万邦生化医药股份有限公司 | lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用 |
| EP3701952A4 (en) * | 2017-10-26 | 2021-06-30 | Otsuka Pharmaceutical Co., Ltd. | INOSITE PHOSPHATE COMPOSITION |
| JP2023525631A (ja) * | 2020-03-15 | 2023-06-19 | アレン ダビドフ | ウイルス感染症及び健康上の影響の治療方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| WO2011032175A1 (en) * | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| US9023856B2 (en) * | 2011-11-04 | 2015-05-05 | Cymabay Therapeutics, Inc. | Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent |
-
2011
- 2011-11-04 NZ NZ624708A patent/NZ624708A/en not_active IP Right Cessation
- 2011-11-04 JP JP2014541011A patent/JP6202633B2/ja not_active Expired - Fee Related
- 2011-11-04 CN CN201180076191.4A patent/CN104066427A/zh active Pending
- 2011-11-04 MX MX2014005400A patent/MX357507B/es active IP Right Grant
- 2011-11-04 KR KR1020147015169A patent/KR20140121383A/ko not_active Abandoned
- 2011-11-04 CN CN201910004813.0A patent/CN109908124A/zh active Pending
- 2011-11-04 SG SG11201402032RA patent/SG11201402032RA/en unknown
- 2011-11-04 AU AU2011380507A patent/AU2011380507B2/en not_active Ceased
- 2011-11-04 WO PCT/US2011/059394 patent/WO2013066349A1/en not_active Ceased
- 2011-11-04 EP EP11875114.8A patent/EP2773336A4/en not_active Withdrawn
- 2011-11-04 CA CA2859686A patent/CA2859686C/en not_active Expired - Fee Related
-
2014
- 2014-04-30 IL IL232386A patent/IL232386A0/en unknown
- 2014-05-02 CL CL2014001155A patent/CL2014001155A1/es unknown
- 2014-05-16 ZA ZA2014/03575A patent/ZA201403575B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014005400A (es) | 2015-02-12 |
| CA2859686C (en) | 2018-09-11 |
| EP2773336A1 (en) | 2014-09-10 |
| AU2011380507B2 (en) | 2017-06-15 |
| AU2011380507A1 (en) | 2014-05-29 |
| JP2014532758A (ja) | 2014-12-08 |
| CN109908124A (zh) | 2019-06-21 |
| EP2773336A4 (en) | 2015-06-03 |
| CA2859686A1 (en) | 2013-05-10 |
| CL2014001155A1 (es) | 2015-01-16 |
| IL232386A0 (en) | 2014-06-30 |
| CN104066427A (zh) | 2014-09-24 |
| JP6202633B2 (ja) | 2017-09-27 |
| MX357507B (es) | 2018-07-12 |
| ZA201403575B (en) | 2015-11-25 |
| WO2013066349A1 (en) | 2013-05-10 |
| KR20140121383A (ko) | 2014-10-15 |
| SG11201402032RA (en) | 2014-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012184234A5 (enExample) | ||
| NZ624708A (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| EA018193B3 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| NZ601121A (en) | 5-alkynyl-pyrimidines | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| AU2011201462B2 (en) | Method of Administering Pirfenidone Therapy | |
| PE20170306A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| BR112013022332A2 (pt) | métodos para tratamento e/ou prevenção de hiperuricemia ou de um distúrbio metabólico associado com a hiperuricemia, e para melhorar o controle do nível de ácido úrico no sangue, e, composição farmacêutica | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| EA201490928A1 (ru) | Способы лечения острых приступов подагры | |
| GEP20115342B (en) | New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | |
| MY182983A (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
| PH12013500411A1 (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| MX2022009874A (es) | Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4). | |
| WO2010090494A3 (ko) | 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도 | |
| MX2012009600A (es) | Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa. | |
| NZ706740A (en) | Use of vap-1 inhibitors for treating fibrotic conditions | |
| CA2902116C (en) | Pyrrolopyridine derivatives and their use as inhibitors of ssao activity | |
| PH12014502282A1 (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| BR112014009165A8 (pt) | sal e uso médico | |
| JP2014532758A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 NOV 2018 BY AJ PARK Effective date: 20160502 |
|
| ASS | Change of ownership |
Owner name: CYMABAY THERAPEUTICS, INC., US Effective date: 20170309 Owner name: DIATEX, INC., NZ Effective date: 20170309 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2019 BY CPA GLOBAL Effective date: 20180920 |
|
| LAPS | Patent lapsed |